Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Genetics

• Publication date

  2004-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1399-0004.2004.00284.xPMID 15253767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry Disease: A Prospective Strain Rate Imaging Study

  2003cited by this paper
• Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging

  2003influential reference
• PR interval and the response to enzyme-replacement therapy for Fabry's disease.

  2003cited by this paper
• Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy.

  2002cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease

  2001cited by this paper
• Natural history of Fabry disease in affected males and obligate carrier females

  2001cited by this paper
• Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

  2001cited by this paper
• Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes

  2001cited by this paper
• Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

  2001cited by this paper
• Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.

  2001cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease

  2001cited by this paper
• α-Galactosidase A deficiency. Fabry disease

  2001cited by this paper
• SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE

  2001influential reference
• New insights in cardiac structural changes in patients with Fabry's disease.

  2000cited by this paper
• Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis.

  1999cited by this paper
• Gaucher's disease: a model for modern management of a genetic disease.

  1999cited by this paper
• Prevalence of lysosomal storage disorders.

  1999cited by this paper
• Enzyme therapy for Gaucher disease: the first 5 years.

  1998cited by this paper
• Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease: critical role of left ventricular systolic function.

  1997cited by this paper
• An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

  1995cited by this paper
• Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures.

  1993cited by this paper
• Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

  1992influential reference
• An atypical variant of Fabry's disease with manifestations confined to the myocardium.

  1991cited by this paper
• Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease

  1990cited by this paper
• Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

  1986cited by this paper

• Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down‐Regulation of Mannose‐6‐Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy

  2025cites this paper
• Identification of Four New Mutations in the GLA Gene Associated with Anderson–Fabry Disease

  2025cites this paper
• A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta

  2025cites this paper
• Enzyme replacement therapy in Fabry cardiomyopathy: an incomplete treatment

  2024cites this paper
• The Importance of Early Treatment of Inherited Neuromuscular Conditions

  2024cites this paper
• Algorithm for Investigation of Fabry Disease in Cardiomyopathies

  2024cites this paper
• Anderson–Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement

  2024cites this paper
• Treatment of Fabry Disease: Established and Emerging Therapies

  2023cites this paper
• Cardiac involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring.

  2022cites this paper
• Arrhythmia Burden and Heart Rate Response During Exercise in Anderson-Fabry Disease.

  2022cites this paper
• Fabry Disease: current & novel therapeutic strategies. A narrative review.

  2022cites this paper
• Gastrointestinal Manifestations and Treatment Options in Fabry Disease Patients. A Systematic Review.

  2022cites this paper
• Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis

  2022cites this paper
• Current status of cardiac manifestations in Fabry disease and their treatment

  2021cites this paper
• Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy

  2020cites this paper
• Therapeutic advances in Fabry disease: The future awaits.

  2020cites this paper
• Treatment of Anderson-Fabry disease.

  2020cites this paper
• Deposit Diseases as Differential Diagnosis of Left Ventricular Hypertrophy in Patients with Heart Failure and Preserved Systolic Function

  2019cites this paper
• The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

  2019cites this paper
• The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease.

  2019cites this paper
• Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

  2018cites this paper
• The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.

  2018cites this paper
• Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease

  2018cites this paper
• Echocardiographic Assessment of Patients with Fabry Disease

  2018cites this paper
• Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy.

  2017cites this paper
• Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies

  2017cites this paper
• Echocardiographic role in the detection and monitoring of Anderson-Fabry disease

  2017cites this paper
• Molecular and clinical studies in five index cases with novel mutations in the GLA gene.

  2016cites this paper
• Enzyme replacement therapy for Anderson-Fabry disease.

  2016cites this paper
• Constrictive Pericarditis Versus Restrictive Cardiomyopathy?

  2016cites this paper
• Arrhythmias in Fabry cardiomyopathy.

  2015cites this paper
• Fabry cardiomyopathy is a multisystem disorder with important cardiovascular involvement. Arrhythmias can cause significant morbidity and mortality in Fabry disease. Fabry disease can be diagnosed by measurement of plasma a-galactosidase A or mutation

  2015cites this paper
• A case study of a 59-year-old male with a cardiac variant of Anderson–Fabry disease

  2015cites this paper
• Fabry disease.

  2015cites this paper
• Fabry disease and the heart.

  2015cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2015cites this paper
• Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis

  2014cites this paper
• Therapies for Lysosomal Storage Diseases

  2013cites this paper
• Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry

  2013cites this paper
• Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy.

  2013cites this paper
• A case of Fabry cardiomyopathy presenting with ventricular tachycardia and chest pain

  2013cites this paper
• Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry’s disease

  2013cites this paper
• Fabry Disease (α-Galactosidase A Deficiency)

  2013cites this paper
• Enzyme replacement therapy improves cardiac features and severity of Fabry disease.

  2012cites this paper
• Spotlight on Agalsidase Beta in Fabry Disease1

  2012cites this paper
• Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy

  2012cites this paper
• Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Münster Study (FaMüS) data

  2012cites this paper
• Heart in Fabry Disease

  2012cites this paper
• Arrhythmias in Fabry Cardiomyopathy

  2012cites this paper
• Agalsidase Beta

  2012cites this paper
• Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

  2012cites this paper
• Lysosomal Storage Diseases To date

  2011cites this paper
• Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.

  2011cites this paper
• The heart in Fabry's disease.

  2011cites this paper
• Electrocardiographic changes in early recognition of Fabry disease

  2011cites this paper
• Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy

  2011cites this paper
• Echocardiographic assessment of fabry cardiomyopathy: early diagnosis and follow-up.

  2011cites this paper
• The Heart in Fabry Disease – from Pathogenesis to Enzyme Replacement Therapy

  2010cites this paper
• Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy

  2010cites this paper
• Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.

  2010cites this paper
• Fabry disease: a review of current management strategies.

  2010cites this paper
• [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].

  2010cites this paper
• Therapeutic goals in the treatment of Fabry disease

  2010cites this paper
• Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature

  2010cites this paper
• [Management of Fabry disease].

  2010cites this paper
• A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.

  2010cites this paper
• Management of Fabry Disease with Agalsidase Treatment

  2010cites this paper
• Age adjusting severity scores for Anderson-Fabry disease.

  2010cites this paper
• Cardiac challenges in patients with Fabry disease.

  2010cites this paper
• The Price of Care Versus the Cost of Caring

  2010cites this paper
• Catheter Ablation of Reentrant Left Ventricular Tachycardia Associated with Fabry disease: A Case Report

  2010cites this paper
• Manifestations cardiaques de la maladie de Fabry et données d’efficacité de l’enzymothérapie

  2010cites this paper
• Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion

  2010cites this paper
• Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring

  2009cites this paper
• Effects of enzyme-replacement therapy in patients with Anderson–Fabry disease: a prospective long-term cardiac magnetic resonance imaging study

  2009cites this paper
• Fabry sykdom hos kvinner : Symptomer, organmanifestasjoner og livskvalitet

  2009cites this paper
• Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences.

  2009cites this paper
• Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.

  2009cites this paper
• Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey

  2009cites this paper
• Fabry disease.

  2009cites this paper
• Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy

  2009cites this paper
• Cardiac Microvascular Pathology in Fabry Disease: Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy

  2009cites this paper
• Fabry Disease (α-Galactosidase A Deficiency): An X-linked Nephropathy

  2009cites this paper
• Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

  2008influential citation
• Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement

  2008cites this paper
• Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.

  2008cites this paper
• Fabry's disease.

  2008cites this paper
• Lysosomal Storage Disease 3 Fabry's disease

  2008cites this paper
• Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and dose.

  2008cites this paper
• Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

  2008cites this paper
• Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes.

  2008cites this paper
• Cardiac performance during exercise in patients with Fabry's disease

  2008cites this paper
• Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy

  2007cites this paper
• Enzyme-deficiency metabolic cardiomyopathies and the role of enzyme replacement therapy

  2007cites this paper
• Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature

  2007cites this paper
• Fabry's Cardiomyopathy: Diagnosis, Pathophysiology and the Role of Enzyme Replacement Therapy

  2007cites this paper
• Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

  2007cites this paper
• Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey

  2007cites this paper
• Active‐site‐specific chaperone therapy for Fabry disease

  2007cites this paper
• Spotlight on agalsidase beta in Fabry disease.

  2007cites this paper